In the preceding three months, 15 analysts have released ratings for Albemarle ALB, presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 4 | 7 | 1 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 2 | 2 | 0 | 0 |
2M Ago | 2 | 1 | 1 | 0 | 0 |
3M Ago | 1 | 1 | 3 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $138.67, a high estimate of $162.00, and a low estimate of $81.00. Observing a 3.93% increase, the current average has risen from the previous average price target of $133.43.
Interpreting Analyst Ratings: A Closer Look
The standing of Albemarle among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Ben Isaacson | Scotiabank | Lowers | Sector Perform | $135.00 | $150.00 |
Corinne Blanchard | Deutsche Bank | Raises | Hold | $140.00 | $125.00 |
Ben Isaacson | Scotiabank | Lowers | Sector Outperform | $150.00 | $160.00 |
Arun Viswanathan | RBC Capital | Raises | Outperform | $157.00 | $138.00 |
John Roberts | Mizuho | Raises | Neutral | $128.00 | $112.00 |
Michael Sison | Wells Fargo | Raises | Overweight | $145.00 | $135.00 |
Andres Castanos Mollor | Berenberg | Raises | Buy | $160.00 | $130.00 |
Patrick Cunningham | Citigroup | Raises | Neutral | $135.00 | $125.00 |
Matthew DeYoe | B of A Securities | Raises | Buy | $156.00 | $137.00 |
Christopher Kapsch | Loop Capital | Lowers | Buy | $162.00 | $168.00 |
Vincent Andrews | Morgan Stanley | Lowers | Underweight | $81.00 | $90.00 |
Kevin McCarthy | Vertical Research | Announces | Hold | $145.00 | - |
John Roberts | Mizuho | Lowers | Neutral | $112.00 | $115.00 |
Aleksey Yefremov | Keybanc | Lowers | Overweight | $159.00 | $178.00 |
John Roberts | Mizuho | Raises | Neutral | $115.00 | $105.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Albemarle. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Albemarle compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Albemarle's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Albemarle's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Albemarle analyst ratings.
Delving into Albemarle's Background
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.
Albemarle: Financial Performance Dissected
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Albemarle's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -47.26% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Albemarle's net margin is impressive, surpassing industry averages. With a net margin of -0.67%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Albemarle's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.1%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Albemarle's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Albemarle's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.38.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.